aplastic anemia,AA
Conditions
Interventions
Cass series:low dose post Cyclophosphamide and Mesenchymal stem cell
Sponsors
Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 14 to 50 years old; 2. ECOG score < 2 (Appendix 2); 3. AA was diagnosed by definite blood routine, reticulocyte count, multi-site bone marrow puncture and bone marrow biopsy. 4. At present, patients have no other effective treatment, or patients choose allo-HSCT voluntarily. 5. The main organs and tissues of the patients have good functions: (1) cardiac function: without heart disease or coronary heart disease, the heart function of the patients is grade 1-2 (Appendix 3); (2) liver function: TBIL < 3ULN, AST < 2.5ULN, ALT < 2.5ULN; (3) renal function: Cr < 1.25ULN; 6. The peripheral superficial venous blood passage of the patient is unobstructed, which can meet the needs of intravenous drip. 7. The patient himself agreed to participate in the clinical study and signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Systemic active infections requiring treatment; 2. suffer from serious heart, liver, kidney dysfunction and other diseases; 3. HIV infected patients; 4. suffering from serious autoimmune diseases or immunodeficiency diseases; 5. Severe allergic constitution; 6. Severe mental disorders; 7. Other clinical trial researchers who have participated in or are currently participating in the past three months; 8. With other serious diseases (such as autoimmune diseases and immunodeficiency) that conflict with this program; 9. With history of other malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Routine blood test;Osseous puncture;electrocardiogram;Color Doppler ultrasound;CT;Biochemical indicators; | — |
Countries
China
Contacts
Public ContactZhou Jian
Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital
Outcome results
None listed